Literature DB >> 2689351

Resistance to third generation cephalosporins: the current situation.

J C Pechère1.   

Abstract

Newer beta-lactam antibiotics, notably the third generation cephalosporins (3 GC) have been designed for providing high intrinsic potency against a large variety of microorganisms. Bacterial resistance can occur however, and nowadays, clinicians are concerned by novel situations where even most recently developed compounds can be ineffective. A first situation is generated by bacteria which produce great amounts of chromosomal cephalosporinase. The resistance emerges during therapy, in hospital isolates which are classified as susceptible with conventional susceptibility testing. The prevalence of 3 GC resistance among these gram-negative rods with inducible beta-lactamase seems to increase in some institutions but the significance of susceptibility testing in this regard is doubtful. It is probably more important to note that the prevalence of gram-negative rods with inducible beta-lactamases remains stable. A second problem arose with the abrupt development of plasmid mediated beta-lactamases markedly active against 3 GC. This resistance is underestimated because some strains fall into susceptibility range of 3 GC as determined by MICs or inhibition zone sizes. These extended spectrum enzymes are now distributed over four continents and represent a growing threat.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2689351     DOI: 10.1007/bf01650724

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  37 in total

1.  An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre.

Authors:  S S Pedersen; C Koch; N Høiby; K Rosendal
Journal:  J Antimicrob Chemother       Date:  1986-04       Impact factor: 5.790

2.  Effect of interaction between outer membrane permeability and beta-lactamase production on resistance to beta-lactam agents in gram-negative bacteria.

Authors:  T Sawai; A Yamaguchi; R Hiruma
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

3.  Combination therapy: a way to limit emergence of resistance?

Authors:  M Michéa-Hamzehpour; J C Pechère; B Marchou; R Auckenthaler
Journal:  Am J Med       Date:  1986-06-30       Impact factor: 4.965

4.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

5.  Common mechanism of ampC beta-lactamase induction in enterobacteria: regulation of the cloned Enterobacter cloacae P99 beta-lactamase gene.

Authors:  F Lindberg; S Normark
Journal:  J Bacteriol       Date:  1987-02       Impact factor: 3.490

6.  Beta-lactamase lability and inducer power of newer beta-lactam antibiotics in relation to their activity against beta-lactamase-inducibility mutants of Pseudomonas aeruginosa.

Authors:  D M Livermore; Y J Yang
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

7.  Penicillinases of Klebsiella pneumoniae and their phylogenetic relationship to penicillinases mediated by R factors.

Authors:  T Sawai; S Yamagishi; S Mitsuhashi
Journal:  J Bacteriol       Date:  1973-09       Impact factor: 3.490

8.  Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens.

Authors:  H Knothe; P Shah; V Krcmery; M Antal; S Mitsuhashi
Journal:  Infection       Date:  1983 Nov-Dec       Impact factor: 3.553

9.  Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats.

Authors:  D E Johnson; B Thompson; F M Calia
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

10.  Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.

Authors:  A S Bayer; D Norman; K S Kim
Journal:  Antimicrob Agents Chemother       Date:  1985-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.